Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

32.21 -1.24 (-3.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 741,044
Open 34.00
Bid (Size) 31.60 (2)
Ask (Size) 32.90 (1)
Prev. Close 33.45
Today's Range 31.94 - 34.00
52wk Range 28.04 - 73.27
Shares Outstanding 76,217,463
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
Beam Therapeutics to Participate in Upcoming May Investor Conferences
From Beam Therapeutics
Via GlobeNewswire

Performance

YTD
-13.69%
-13.69%
1 Month
-6.66%
-6.66%
3 Month
-7.47%
-7.47%
6 Month
-27.93%
-27.93%
1 Year
-19.84%
-19.84%

More News

Read More
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
Via The Motley Fool
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics: Q1 Earnings Insights
Via Benzinga
Where Beam Therapeutics Stands With Analysts
Via Benzinga
Where Beam Therapeutics Stands With Analysts
Via Benzinga
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
7 Best Cathie Wood Stocks for Your May 2023 Buy List
Via InvestorPlace
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
Via The Motley Fool
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Via InvestorPlace
Cathie Wood Is Unstoppable With Tesla Stock – Defies Wall Street To Make Whopping $29M Purchase
Via Benzinga
3 Stocks to Watch in April: Is it Time to Buy?
Via InvestorPlace
7 Top Growth Stocks to Buy for the Next Decade
Via InvestorPlace
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
Via InvestorPlace
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Beam Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
Via InvestorPlace
3 Game-Changing Stocks to Buy in March
Via The Motley Fool
The Top 7 Growth Stocks in Biotech
Via InvestorPlace
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.